917808-08-3

Usage

General Description

1-Piperidinecarboxylic acid, 4-[4-(4-fluorophenyl)-5-[2-(methylthio)-4-pyrimidinyl]-2-thiazolyl]-, 1,1-dimethylethyl ester is a chemical compound that belongs to the class of piperidinecarboxylic acid derivatives. It is also known as the trelagliptin benzoate, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes. Trelagliptin benzoate works by increasing insulin production in the body and reducing the amount of glucose produced by the liver. It is often used in combination with other diabetes medications and is available in tablet form for oral administration. 1-Piperidinecarboxylic acid, 4-[4-(4-fluorophenyl)-5-[2-(methylthio)-4-pyrimidinyl]-2-thiazolyl]-, 1,1-dimethylethyl ester has been found to be effective in improving glycemic control in patients with type 2 diabetes, making it a valuable tool in the management of this condition.

Upstream product

• 214834-18-1 tert-butyl 4-carbamothioylpiperidine-1-carboxylate 
• 217661-99-9 1-(4-fluorophenyl)-2-(2-methylsulphanylpyrimidin-4-yl)-1-ethanone 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 14001-63-9 2-methylthio-4-methylpyrimidine 

Downstream Products

• 917812-43-2 4-[4-(4-fluorophenyl)-2-(1-methylpiperidin-4-yl)thiazol-5-yl]-2-methylsulfanylpyrimidine 

Relevant academic research and scientific papers

Trisubstituted thiazoles as potent and selective inhibitors of Plasmodium falciparum protein kinase G (PfPKG)

A series of trisubstituted thiazoles have been identified as potent inhibitors of Plasmodium falciparum (Pf) cGMP-dependent protein kinase (PfPKG) through template hopping from known Eimeria PKG (EtPKG) inhibitors. The thiazole series has yielded compounds with improved potency, kinase selectivity and good in vitro ADME properties. These compounds could be useful tools in the development of new anti-malarial drugs in the fight against drug resistant malaria.

NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed relates to new substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppresion and inflammation inhibitory activity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The compound of the present invention having excellent TNF-α inhibitory activity and inflammation inhibitory activity can be effectively used in the prevention and treatment of TNF-α related diseases.